Monoprost (Latanoprost)

Latanoprost is a prostaglandin F‑type (FP) receptor agonist. It increases the outflow of aqueous humor through the uveoscleral pathway, which lowers intra‑ocular pressure and reduces the risk of glaucoma‑related vision loss.

The dosing regimen for Monoprost is determined by the prescribing ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and schedule must follow the prescriber's instructions.

The safety of latanoprost in pregnancy or lactation has not been fully established. Healthcare providers should weigh potential benefits against risks and consider alternative treatments if the patient is pregnant or nursing.

To request Monoprost, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Monoprost belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong intra‑ocular pressure reduction. Compared with beta‑blocker or carbonic anhydrase inhibitor drops, prostaglandin analogs often have a more favorable dosing convenience but may cause cosmetic changes such as iris darkening.

Monoprost should be stored at room temperature, below 25 °C. Keep the bottle in its original packaging, protect it from direct light and moisture, and discard any solution that appears discolored or contains particles.

Monoprost is applied as a single drop into the conjunctival sac of the affected eye(s) once daily, preferably in the evening. The patient should avoid touching the tip of the bottle to the eye or any surface to maintain sterility.

Serious risks include severe allergic reactions, uveitis, macular edema, and sudden vision loss. Patients should seek immediate medical attention if they experience eye pain, redness, swelling, or any rapid change in vision.

Monoprost is contraindicated in patients with active ocular inflammation, known hypersensitivity to latanoprost or any component of the formulation, and should be used with caution in individuals with a history of intra‑ocular inflammation or retinal disease.